Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Galena Biopharma Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 -
EBIT 2016 -33,8 M
Net income 2016 -24,0 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -28,6 M
Net income 2017 -33,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 0
Capi. / Sales2017 0
Capitalization 19,6 M
More Financials
Company
Galena Biopharma, Inc. engages as a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs.It focuses on identifying and advancing therapeutic opportunities to improve cancer care from direct treatment of... 
Sector
Pharmaceuticals
Calendar
03/29Earnings Release
More about the company
Surperformance© ratings of Galena Biopharma Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on GALENA BIOPHARMA INC
01/09 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Other Events
01/09 GALENA BIOPHARMA, INC. : Other Events (form 8-K)
01/06 GALENA BIOPHARMA : to Provide Corporate and Clinical Update and 2017 Outlook Dur..
01/05 Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook Du..
2016 GALENA BIOPHARMA INC : Galena Biopharma Pipeline Developments Third Quarter 2016..
2016 Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Control..
2016 GALENA BIOPHARMA, INC. (NASDAQ : GALE) Files An 8-K Other Events
2016 GALENA BIOPHARMA, INC. : Other Events (form 8-K)
2016 Galena Biopharma Announces the Phase 2 Clinical Trial of NeuVax™ (nelip..
2016 GALENA BIOPHARMA : Presented Two Posters at the San Antonio Breast Cancer Sympos..
More news
Sector news : Pharmaceuticals - NEC
12:08p Drugmakers in Davos shift focus to chronic diseases of poor
08:49aDJBayer Joins Jobs Parade -- WSJ
01:56aDJBAYER : Will Keep Monsanto Jobs in U.S., Trump Team Says -- 2nd Update
12:05aDJAllergan Admits to Disclosure Violations During Valeant Bid
01/17 Allergan to pay $15 million over failing to disclose merger talks
More sector news : Pharmaceuticals - NEC
Latest Tweets
01/12Galena Biopharma (GALE) Presents At 35th Annual J.P. Morgan Healthcare Confer.. 
01/05$GALE: Galena Biopharma provided a corporate and clinical outlook for 2017 an.. 
01/05Galena Biopharma's outperform rating reiterated at FBR & Co. $11.00 PT. .. 
01/03Galena Biopharma's buy rating reiterated at Maxim Group. $4.00 PT.  
More tweets
Qtime:61
News from SeekingAlpha
2016 Galena Biopharma's (GALE) CEO Mark Schwartz on Q3 2016 Results - Earnings Cal..
2016 Galena Biopharma beats by $0.02
2016 Notable earnings after Wednesday?s close
2016 RXI PHARMACEUTICALS : Moving On Promising Scar Treatment
2016 Best And Worst Performing Stocks Of 2016
Advertisement
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | US3632561086 | 4-Traders
Full-screen chart
Technical analysis trends GALENA BIOPHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 7,67 $
Spread / Average Target 324%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark W. Schwartz President, Chief Executive Officer & Director
Sanford J. Hillsberg Chairman
Gavin S. Choy Senior VP-Clinical Sciences & Operations
Stephen F. Ghiglieri Chief Financial Officer & Executive Vice President
Bijan Nejadnik Chief Medical Officer & Executive Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GALENA BIOPHARMA INC-87.52%20
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results